2011
OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.
Mayer E, Ligibel J, Burstein H, Peppercorn J, Miller K, Carey L, Dickler M, Mayer I, Forero A, Eng-Wong J, Pletcher P, Ryabin N, Gelman R, Wolff A, Winer E. OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. Cancer Research 2011, 71: ot3-02-04-ot3-02-04. DOI: 10.1158/0008-5472.sabcs11-ot3-02-04.Peer-Reviewed Original ResearchPreoperative chemotherapyBreast cancerLifestyle interventionPhase II Randomized StudyAcceptable organ functionResidual invasive diseaseAdjuvant combination chemotherapyTaxane-based chemotherapyRecurrence-free survivalResidual breast cancerRisk of recurrenceFuture clinical trialsStructured exercise programImpact of exerciseAnti-angiogenic agentsUnmet medical needContribution of exerciseQuality of lifeYear BAdjuvant bevacizumabDFCI 05Eligible ptsLast surgeryNeoadjuvant chemotherapyPrimary endpoint
2007
A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer
Mayer E, Miller K, Rugo H, Peppercorn J, Carey L, Ryabin N, Winer E, Burstein H. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. Journal Of Clinical Oncology 2007, 25: 561-561. DOI: 10.1200/jco.2007.25.18_suppl.561.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerAdjuvant bevacizumabAntiangiogenic therapyAnthracycline-containing neoadjuvant chemotherapyHigh-risk breast cancerAdjuvant antiangiogenic therapyResidual invasive carcinomaSingle-agent bevacizumabCycles of therapyTreatment-related toxicityChemotherapy-resistant diseasePhase II trialResidual breast cancerRisk of recurrenceNovel antiangiogenic therapiesEligible patientsMild arthralgiaAgent bevacizumabBevacizumab monotherapyII trialPrimary endpointMedian ageOngoing trialsOral chemotherapy